Ein interessanter Beitrag, besonders
“Many years ago, when I was early in my MS career, I asked the head of neuropathology at Queen Square, my previous institution, how common MS and AZD were found at post-mortem. He said to me that in over 200 brain bank MS cases, he had never seen both MS and AZD. He had good data on this because the brain bank’s protocol for processing tissue included staining for amyloid or AZD pathology. And the head of neuropathology was a very good pathologist. It is a pity we never wrote up this finding. However, since then, I have assumed that pwMS are protected from getting AZD.
A recent study published in the Annals of Neurology showed that pwMS have lower amyloid-β plasma positivity, a marker of AZD pathology, compared to non-MS controls (see paper below). This observation is very important as it may tell us something about the pathogenesis of AZD and could lead to new and exciting ways to prevent and treat AZD. I have lots of ideas about why MS protects you from getting AZD, but not enough time to research them.”
Hat jemand hier schon etwas ähnliches gehört bzw. gelesen?